Ritonavir-boosted protease inhibitor based therapy: A new strategy in chronic hepatitis C therapy

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 5, 2015, Pages 547-558

  Brayer, Samuel W ^a   Reddy, K Rajender ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CYP3A4; direct acting antiviral; hepatitis C; protease inhibitor; ritonavir

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; DASABUVIR; GEMFIBROZIL; KETOCONAZOLE; OMBITASVIR; PARITAPREVIR; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; ABT-450; ANTIVIRUS AGENT; MACROCYCLIC COMPOUND;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENZYME INHIBITION; FATIGUE; FIRST PASS EFFECT; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; LIVER CIRRHOSIS; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG INTERACTION; HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; MACROCYCLIC COMPOUNDS; PROTEASE INHIBITORS; RITONAVIR;

EID: 84928543184     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1032938     Document Type: Article

References (64)

1. Klevens RM, Hu DJ, Jiles R, et al. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis 2012; 55: S3-9
2. Kohli A, Shaffer A, Sherman A, et al. Treatment of hepatitis C: a systematic review. JAMA 2014; 312: 631-40
3. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98
4. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21
5. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N Engl J of Med 2014; 370: 1993-2001
6. Lawitz E Poordad F Brainard DM et al. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2014
7. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93
8. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014
9. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-605
10. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91
11. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med 2014; 370: 1983-92
12. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. New England J Med 2014; 370(17): 1594-603
13. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-14
14. Backus LI, Boothroyd DB, Phillips BR, etal. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol and Hepatol 2011; 9: 509-16.e501
15. Morgan RL, Baack B, Smith BD, et al.Virus Infection and the Development of Hepatocellular CarcinomaA Meta-analysis of Observational Studies. Ann Intern Med 2013; 158: 329-37
16. Van Der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93
17. Younossi ZM, Singer ME, Mir HM, et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. Hepatology 2014; 60: 530-7
18. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-63
19. Tan S-L, He Y, Staschke et al. HCV NS5A: A Multifunctional Regulator of Cellular Pathways and Virus Replication. Horizon Bioscience 2006
20. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha 2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-9
21. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503
22. Kempf DJ, Sham HL, Marsh KC, et al. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 1998; 41: 602-17
23. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995; 69: 701-6
24. Hosur MV, Bhat TN, Kempf DJ, et al. Influence of stereochemistry on activity and binding modes for C2 symmetry-based diol inhibitors of HIV-1 protease. J Am Chem Soc 1994; 116: 847-55
25. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60
26. Moyle G, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-13
27. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. JAIDS 2002; 29: S11-18
28. Zhou S-F, Xue CC, Yu X-Q, et al. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710
29. Rathbun RC, Rossi DR. Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement. Ann Pharmacother 2002; 36: 702-6
30. Kempf DJ, Marsh KC, Denissen JF et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995. 92: 2484-8
31. Bruno R, Cima S, Maiocchi L, Sacchi P. Forthcoming challenges in the management of direct-acting antiviral agents (DAAs) for hepatitis C. Dig Liver Dis 2011; 43: 337-44
32. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 4-9
33. Fromm M. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38: 69-74
34. Jones K, Bray PG, Khoo SH, et al. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?. Aids 2001; 15: 1353-8
35. Janneh O, Jones E, Chandler B, et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-93
36. Bierman WF, Scheffer GL, Schoonderwoerd A, et al Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 2010; 65(8): 1672-80
37. Bessadok A, Garcia E, Jacquet H, et al. Recognition of Sulfonylurea Receptor (ABCC8/9) Ligands by the Multidrug Resistance Transporter P-glycoprotein (ABCB1) functional similarities based on common structural features between two multispecific abc proteins. J Biol Chem 2011; 286: 3552-69
38. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47-54
39. Zhou S-F Wang L-L Di YM et al. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008 15:1981-2039
40. Mosure KW Knipe JO Browning M et al. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. J Pharm Sci 2015 doi: 10.1002/jps.24356 Epub ahead of print]
41. Ogasawara K, Terada T, Katsura T, et al. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab Pharmacokinet 2010; 25: 190-9
42. Menon R, Badri P, Wang T, et al. Drug-drug Interaction Profile of the All-Oral Anti-Hepatitis C Virus Regimen of Paritaprevir/Ritonavir, Ombitasvir and Dasabuvir. J Hepatol 2015; doi: 10.1016/j. jhep.2015.01.026. [Epub ahead of print]
43. Kempf DJ, Klein C, Chen H-J, et al. Short communication-Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163
44. Flanagan S, Crawford-Jones A, Orkin C. Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Rev Clin Pharmacol 2014; 7: 691-704
45. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-34
46. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40: 174-1815
47. Pe-rez-Elías MJ Morellon ML Ortega E et al. Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment. Antimicrob Agents Chemother 2009 53 5185-96
48. Herold C, Heinz R, Niedobitek G, et al. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260-5
49. Frye -RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006; 80: 235-45
50. George J, Murray M, Byth K, et al. Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995; 21: 120-8
51. Menon R, Klein C, Lawal A, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Glob Antivir J 2009; 5: 31
52. Bernstein B, Menon R, Klein C, et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers. HepDART Kohala Coast, Hawaii, 2009
53. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53
54. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222-32
55. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17
56. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28
57. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014; 370: 1973-82
58. Viekira Pak. Prescribing Information. North Chicago, IL, 2015
59. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. Aids 2000; 14: 51-7
60. Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-22
61. Sulkowski MS Eron JJ Wyles D et al. Ombitasvir paritaprevir co-dosed with ritonavir dasabuvir and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015 doi: 10.1001/jama.2015.1328 Epub ahead of print]
62. Crauwels HM, Kakuda TN. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet 2010; 49: 67-8
63. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371(25): 2375-82
64. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/Adultand/AdolescentGL.pdf